Cingulate therapeutics filing

Author: dkuh

August undefined, 2024

WebMar 30, 2024 · (a) the Company’s latest annual report on Form 10-K filed pursuant to Section 13(a) or 15(d) of the Exchange Act for the fiscal year ended December 31, 2024, as filed with the Commission on ... WebUncategorized (1) Contracts. Master Services Agreement between Cingulate Therapeutics LLC and Societal CDMO, Inc., dated October 24, 2024 (Filed With SEC on October 25, 2024) Promissory Note, dated August 9, 2024, between Cingulate Therapeutics, LLC and Werth Family Investment Associates LLC (Filed With SEC on August 11, 2024) …

SEC FORM D/A

WebCingulate Therapeutics is a Biotechnology, Pharmaceuticals, and Pharmaceutical Manufacturing company located in Morristown, New Jersey with $2.00 Million in revenue and 14 employees. Find top employees, contact details and business statistics at RocketReach. ... (28 currently) – along with the filing of multiple provisional applications ... WebApr 2, 2024 · About Cingulate Therapeutics. ... Cingulate anticipates filing INDs for both assets in the third and fourth quarters of 2024 and will pursue approval via the accelerated 505(b)(2) regulatory ... the pilbeam cycling holidays

About Cingulate® - Cingulate Inc

WebJun 29, 2024 · The most recently filed 13Fs WebApr 6, 2024 · Cingulate's stock was trading at $1.00 at the beginning of the year. Since then, CING stock has decreased by 3.8% and is now trading at $0.9619. View the best growth stocks for 2024 here. WebMar 10, 2024 · Inside Cingulate Inc.'s 10-K Annual Report: Financial - Expense Highlight. We have experienced, and will continue to experience, increased expenses associated … sidd ahmed net worth

Cingulate Therapeutics - Crunchbase Company Profile

WebAmendment to Employment Agreement, effective April 1, 2024, between Cingulate Therapeutics LLC and Raul R. Silva; Cingulate Inc. Reports First Quarter 2024 Results … WebThe Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. ... Cingulate Therapeutics: Street Address 1 Street Address 2; 1901 W. 47th Place: SUITE 300: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; KANSAS CITY: … the pilchard innWeb1y Target Est. 5.88. Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. … the pilchard press st ives

"WebSep 24, 2014 · Somerset, N.J. – September 24, 2014 — Catalent Pharma Solutions has reached an exclusive development and licensing agreement with privately held biopharmaceutical company, Cingulate Therapeutics (CTx), to support the development of a series of new prescription pharmaceutical products for the treatment of Attention … " - Cingulate therapeutics filing

Cingulate therapeutics filing

Cingulate Inc. Announces Pricing of $25.0 Million Initial Public …

WebCingulate Inc. 1,061 followers. 2mo. Today we announce our Q3 2024 financial results and provided a clinical and business update, including updated study timelines for our lead … WebOct 13, 2024 · Cingulate Therapeutics' IPO date and price. Cingulate is expected to start trading on Oct. 15. The company now plans to raise $40 million by offering 4.4 million …

Did you know?

WebSep 9, 2024 · Cingulate Inc. S-1 Filing information. Filed on 9 September 2024 SEC Edgar 000149315221022284 Exhibits & attachments & exports. ... Top menu > File > Make a … WebJul 11, 2024 · About Cingulate Therapeutics ... Cingulate anticipates filing INDs for both assets in the third and fourth quarters of 2024 and will pursue approval via the accelerated 505(b)(2) regulatory ...

WebCingulate currently has two (2) product candidates, CTX-1301 and CTX-1302, that are being developed to serve the approximate $18 billion annual U.S. ADHD market. A third product candidate, CTX-2103, is being developed to serve the roughly $5 billion U.S. … 10 Mar 2024 Cingulate Inc. Reports Fourth Quarter and Full Year 2024 Financial … Pipeline Overview. Cingulate® completed a proof-of-concept trial in human subjects … Cingulate Inc. 1901 W 47th Place Kansas City, KS 66205 (913) 942-2300 … Shane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and … About Cingulate®. Cingulate® (CTx®)is a Phase 3 clinical stage … Mr. Gallagher is a Co-Founder of Cingulate Therapeutics and serves as a member … The Investor Relations website contains information about Cingulate Inc's … WebSep 9, 2024 · Cingulate Inc. S-1 Filing information. Filed on 9 September 2024 SEC Edgar 000149315221022284 Exhibits & attachments & exports. ... Top menu > File > Make a copy... Copy & paste the following URL into the D2 cell: Do you need help with the setup? Let us know at [email protected]. Close.

WebMay 31, 2024 · Cingulate anticipates filing INDs for CTX-1301 and CTX-1302 via the accelerated 505 (b)(2) regulatory pathway. The company has offices in Kansas City, KS and Morristown, NJ. For more information ... WebShane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and has served as the Chairman and CEO since its inception. Dr. Schaffer is a 25-year pharmaceutical industry veteran with experience in pharmaceutical drug development, commercialization and biotech commercial operations. During his career, he has held positions at Pfizer ...

WebCINGULATE THERAPEUTICS LLC. CINGULATE INC. AND. CINGULATE PHARMA LLC. DATED AS OF AUGUST 30, 2024 . ... 2024, which in turn formed Merger Sub by filing …

WebCompany profile page for Cingulate Therapeutics LLC including stock price, company news, press releases, executives, board members, and contact information siddal pharmacy opening timesWebApr 11, 2024 · On April 04, 2024, Cingulate Inc. (NASDAQ: CING) announced it had completed the first cohort of its Phase 3 adult onset and duration trial of its lead candidate, CTx-1301 (dexmethylphenidate), for attention deficit/hyperactivity disorder (ADHD). The Phase 3 CTx-1301-022 study (NCT05631626) assesses the onset and duration of CTx … siddall \\u0026 hilton products ltdWebJul 10, 2024 · About Cingulate Therapeutics. ... Cingulate anticipates filing INDs for both products in the first quarter of 2024 and will pursue approval via the accelerated 505 (b)(2) regulatory pathway. ... sidcup windows blackfenWebCingulate Therapeutics is based out of Morristown. The firm last filed a Form D notice of exempt offering of securities on 2024-06-29. The notice included securities offered of … the pilcher hamilton corporationWebFunding. Cingulate Therapeutics has raised a total of $7.6M in funding over 3 rounds. Their latest funding was raised on Jul 11, 2024 from a Venture - Series Unknown round. Cingulate Therapeutics is registered under the ticker NASDAQ:CING . Their stock opened with $6.00 in its Dec 8, 2024 IPO. siddalls norwichWebDec 8, 2024 · Cingulate Inc. is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to … siddalls roofing supplies chesterfieldWeb8 rows · Jun 29, 2024 · Cingulate Therapeutics - Most recent fund raising on June 29, 2024 raised $7,000,000 in Equity and Debt siddaganga institute of tech